Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta
Status:
Unknown status
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The treatment of choice for chronic hepatitis D is uncertain. The investigators hypothesize
that pegylated interferon (IFN) alfa-2b in combination with ribavirin (RBV) may be effective
in the treatment of chronic hepatitis D patients who are also infected by hepatitis B virus
(HBV). The purpose of this study is to test this hypothesis. The investigators will use
pegylated IFN alfa-2b in combination with RBV for the treatment of patients with dual chronic
hepatitis D virus (HDV) and HBV infection. A 24-week course of combination therapy pegylated
IFN+RBV will be used.
Phase:
Phase 4
Details
Lead Sponsor:
National Taiwan University Hospital
Collaborators:
National Health Research Institutes, Taiwan National Science Council, Taiwan